Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL9670302 | 0.94 | HDAC1 (0.64) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL9670295 | 0.94 | RAB9A (0.62) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL14461305 | 0.89 | HDAC1 (0.72) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL4929814 | 0.88 | HDAC1 (0.71) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL12588094 | 0.86 | HDAC6 (0.79) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL20509078 | 0.86 | HDAC1 (0.76) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL2639284 | 0.85 | HDAC1 (0.74) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL21296662 | 0.85 | HDAC1 (0.67) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL2639283 | 0.85 | HDAC1 (0.67) | RAB9APOLBLMNATSHRHSD17B10 | |
| SCHEMBL4855534 | 0.85 | HDAC6 (0.67) | RAB9APOLBLMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018144-A1 | Synthesis of EGFR Modulators | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-01-18 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| WO-2011143772-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-5650427-A | ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1997-07-22 | — | — | US | disclosed |
| US-5461061-A | Antidepressants | WIKSTROM HAKAN V (NL) | 1995-10-24 | — | — | US | disclosed |
| US-5288748-A | Antidepressants | THE UPJOHN COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0510068-A1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | PHARMACIA & UPJOHN COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991011435-A2 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | THE UPJOHN COMPANY (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | RAB9A 1430/4885POLB 751/4885LMNA 2203/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | RAB9A 2453/4885POLB 4703/4885LMNA 4359/4885 |
| US-20240018144-A1 | Synthesis of EGFR Modulators | EGFR, ERBB2, ERBB4 | RAB9A 1508/4885POLB 2557/4885LMNA 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.